Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 Sales progress This region was responsible for 15% of the Group’s revenue in FY2021, up from 10% in FY2020 and an impressive four-fold increase in dollar terms. A number of new customer sites were established using SARS-CoV-2 test kits, and encouragingly, discussions are now underway with some of these, and others, about adopting additional tests into their testing portfolios. Part of the transformative effect of FY21 is that the COVID-19 pandemic has led to Genetic Signatures securing its first consistent customers in Europe, leading to sales levels that are almost 27 times what they were just two years ago. Regulatory update In January the company was granted CE-IVD for the EasyScreen ™ STI/Genital Pathogen Kit, allowing the Company to market this product to all 28 European Union member countries plus the UK. Globally the STI testing market is estimated to be $1.9bn pa. This is the 5th diagnostic kit that has achieved CE-IVD registration. GSS Representation EMEA Europe,Middle East and Africa Investor P Direct presence Direct and appointed distributors Appointed distributors Investor Pre Direct presence Direct and appointed distributors Appointed distributors Regions Commercialisation Update